MCID: SKN019
MIFTS: 62

Skin Melanoma malady

Categories: Cancer diseases, Skin diseases, Ear diseases

Aliases & Classifications for Skin Melanoma

Aliases & Descriptions for Skin Melanoma:

Name: Skin Melanoma 12 52 14
Cutaneous Melanoma 12 29 14 69
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Melanoma, Cutaneous Malignant 42
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 69

Classifications:



Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 8 and ocular melanoma, and has symptoms including exanthema and pruritus. An important gene associated with Skin Melanoma is TYR (Tyrosinase), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Mekinist and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
id Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 8 33.9 MITF TYR
2 ocular melanoma 28.8 CDKN1A CDKN2A ERBB2 MMP2 MMP9 PTGS2
3 melanoma, cutaneous malignant, 9 12.3
4 melanoma, cutaneous malignant, 2 12.3
5 melanoma, cutaneous malignant, 3 12.3
6 melanoma, cutaneous malignant, 6 12.3
7 melanoma, cutaneous malignant, 5 12.3
8 melanoma, cutaneous malignant 10 12.2
9 malignant melanoma, somatic 11.1
10 pot1-related susceptibility to cutaneous malignant melanoma 11.1
11 acral lentiginous melanoma 10.9
12 amelanotic melanoma 10.8
13 melanoma 10.6
14 clear cell adenofibroma 10.3 CDKN2A TP53
15 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
16 ampulla of vater neoplasm 10.3 CDKN2A CDKN2B TP53
17 mediastinitis 10.3 MITF PMEL
18 uterine disease 10.3 CDKN2A CDKN2B TP53
19 gallbladder pleomorphic giant cell adenocarcinoma 10.3 CDKN2A NRAS TP53
20 adult epithelioid sarcoma 10.3 CDKN2A NRAS TP53
21 vulval paget's disease 10.3 CDKN2A NRAS TYR
22 well-differentiated thymic neuroendocrine carcinoma 10.3 BRAF TP53
23 spondylarthropathy 10.3 BRAF CDKN2A TP53
24 ossifying fibromyxoid tumor 10.3 CDKN2A NRAS TP53
25 acute disseminated encephalomyelitis 10.3 BRAF CDKN2A NRAS
26 craniosynostosis 6 10.3 MITF PMEL TYR
27 interstitial lung disease 10.3 CDKN2A CDKN2B TP53
28 lung mucoepidermoid carcinoma 10.2 BRAF MITF NRAS
29 cervical verrucous carcinoma 10.2 CDKN1A CDKN2A TP53
30 scarlet fever 10.2 BRAF CDKN1A TP53
31 epilepsy, progressive myoclonic 5 10.2 MITF TYR
32 facio skeletal genital syndrome rippberger type 10.2 MMP2 MMP9
33 chondrodysplasia punctata, rhizomelic, type 3 10.2 CASP3 TP53
34 nelson syndrome 10.2 CDKN2A NRAS PMEL TYR
35 verrucous papilloma 10.2 MITF NRAS PMEL TYR
36 flat ductal epithelial atypia 10.2 CDKN2A FGF2 TP53
37 gallbladder papillomatosis 10.2 CDKN1A MMP2 TP53
38 extraocular retinoblastoma 10.2 CDKN1A CDKN2A TP53
39 subglottis neoplasm 10.2 CDKN1A CDKN2A MMP2
40 leukoencephalopathy palmoplantar keratoderma 10.2 MITF MMP2 MMP9
41 non-distal monosomy 10q 10.2 BRAF CDKN2A NRAS TP53
42 endometrial squamous cell carcinoma 10.2 CDKN2A MLH1 TP53
43 connective tissue benign neoplasm 10.2 CASP3 CDKN2A TP53
44 integumentary system benign neoplasm 10.2 CDKN1A CDKN2A TP53
45 striated muscle rhabdoid tumor 10.2 CDKN2A MMP2 MMP9
46 neurocutaneous melanosis, somatic 10.2 MLH1 NRAS TYR
47 familial hypopituitarism 10.2 BRAF MLH1 TP53
48 toxic megacolon 10.2 CDKN1A MMP9 TP53
49 adenoid squamous cell carcinoma 10.2 CDKN2A MMP2 MMP9
50 autonomic nervous system neoplasm 10.1 CDKN1A CDKN2A CDKN2B TP53

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


exanthema, pruritus

GenomeRNAi Phenotypes related to Skin Melanoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 MLH1 PMEL TP53 CASP3 CDKN1A CDKN2A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 PMEL TP53 BRAF CASP3 CDKN1A CDKN2A

MGI Mouse Phenotypes related to Skin Melanoma:

44 (show all 26)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.49 MCAM MITF MLH1 MMP2 MMP9 NRAS
2 behavior/neurological MP:0005386 10.47 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
3 cellular MP:0005384 10.46 CASP3 CDKN1A CDKN2A CDKN2B ERBB2 FGF2
4 cardiovascular system MP:0005385 10.44 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
5 endocrine/exocrine gland MP:0005379 10.44 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
6 integument MP:0010771 10.44 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
7 hematopoietic system MP:0005397 10.41 CDKN1A CDKN2A CDKN2B FGF2 MCAM MITF
8 growth/size/body region MP:0005378 10.4 MMP9 NME1 NRAS PTGS2 TP53 TYR
9 mortality/aging MP:0010768 10.4 CDKN2A CDKN2B ERBB2 FGF2 MITF MLH1
10 immune system MP:0005387 10.36 CDKN2B MCAM MITF MMP2 MMP9 NRAS
11 digestive/alimentary MP:0005381 10.3 MLH1 MMP9 NRAS PTGS2 TP53 BRAF
12 neoplasm MP:0002006 10.3 MMP9 NME1 NRAS PTGS2 TP53 TYR
13 craniofacial MP:0005382 10.26 BRAF CASP3 CDKN1A ERBB2 MITF MMP2
14 embryo MP:0005380 10.25 TP53 TYR BRAF CDKN1A CDKN2A ERBB2
15 nervous system MP:0003631 10.25 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
16 muscle MP:0005369 10.18 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
17 no phenotypic analysis MP:0003012 10.14 CASP3 CDKN1A CDKN2A CDKN2B MCAM MITF
18 hearing/vestibular/ear MP:0005377 10.12 BRAF CASP3 CDKN1A FGF2 MITF TP53
19 limbs/digits/tail MP:0005371 10.07 CDKN1A ERBB2 MITF MMP9 NRAS TP53
20 reproductive system MP:0005389 10.07 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
21 liver/biliary system MP:0005370 10.05 BRAF CDKN1A CDKN2A NME1 NRAS PTGS2
22 pigmentation MP:0001186 9.97 BRAF CASP3 CDKN2A MITF NRAS PMEL
23 renal/urinary system MP:0005367 9.92 BRAF CASP3 CDKN1A CDKN2B MMP9 PTGS2
24 respiratory system MP:0005388 9.85 BRAF CASP3 CDKN1A CDKN2A ERBB2 MLH1
25 skeleton MP:0005390 9.77 FGF2 MIA MITF MMP2 MMP9 PTGS2
26 vision/eye MP:0005391 9.47 MMP2 MMP9 NRAS PMEL PTGS2 TP53

Drugs & Therapeutics for Skin Melanoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Mekinist 17 46 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline Approved May of 2013

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 362)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Dasatinib Approved, Investigational Phase 4,Phase 2 302962-49-8 3062316
3
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
5
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
6
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
7
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
8
Vindesine Approved Phase 4 59917-39-4, 53643-48-4 40839
9
Aminolevulinic acid Approved Phase 4,Phase 2 106-60-5 137
10
Etanercept Approved, Investigational Phase 4 185243-69-0
11
Bortezomib Approved, Investigational Phase 4,Phase 1,Phase 2 179324-69-7 387447 93860
12
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
13
Sunitinib Approved, Investigational Phase 4,Phase 2 341031-54-7, 557795-19-4 5329102
14
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
15
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
16
Edetic Acid Approved, Vet_approved Phase 4,Phase 3 60-00-4, 62-33-9 6049
17
Palbociclib Approved Phase 4,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
18
Vorinostat Approved, Investigational Phase 4,Phase 1,Phase 2 149647-78-9 5311
19
Ramucirumab Approved, Investigational Phase 4,Phase 1 947687-13-0
20
Technetium tc 99m sulfur colloid Approved Phase 4
21
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
22
Crizotinib Approved Phase 4 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
23
Olaparib Approved Phase 4 763113-22-0 23725625
24
Ceritinib Approved Phase 4 1032900-25-6
25
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2 231277-92-2, 388082-78-8 208908 9941095
26 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 interferons Phase 4,Phase 3,Phase 2,Phase 1
28 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Gastrointestinal Agents Phase 4,Phase 1,Phase 2
31 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Dermatologic Agents Phase 4,Phase 1,Phase 2
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
38 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
39 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
40 Antifungal Agents Phase 4,Phase 2,Phase 1
41 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
43 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Antirheumatic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
45 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
46 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Imatinib Mesylate Phase 4,Phase 2,Phase 1 123596
48 Chelating Agents Phase 4,Phase 3,Phase 1,Phase 2
49 Technetium Tc 99m Pentetate Phase 4,Phase 3
50 Dextrans Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 824)
id Name Status NCT ID Phase
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4
2 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4
3 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
4 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4
5 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4
6 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4
7 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4
8 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4
9 Assessment and Tracking of Long-term Alefacept Safety Terminated NCT00454701 Phase 4
10 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
11 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
12 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
13 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
14 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3
15 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
16 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3
17 Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin Completed NCT00003444 Phase 3
18 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3
19 PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) Completed NCT00221702 Phase 3
20 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
21 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed NCT00019682 Phase 3
22 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3
23 Evaluation of Pigmented Skin Lesions With MelaFind(R) System Completed NCT00434057 Phase 3
24 Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Completed NCT00002882 Phase 3
25 Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Completed NCT00072124 Phase 3
26 Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma Completed NCT00003027 Phase 3
27 S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Completed NCT00006237 Phase 3
28 Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma Completed NCT00002892 Phase 3
29 Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis Completed NCT00004196 Phase 3
30 Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma Completed NCT00016263 Phase 3
31 Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma Completed NCT00039000 Phase 3
32 Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB Completed NCT00204529 Phase 3
33 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3
34 An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Completed NCT01368276 Phase 3
35 Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma Completed NCT00769704 Phase 3
36 Trial of Dacarbazine With or Without Genasense in Advanced Melanoma Completed NCT00518895 Phase 3
37 Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00003647 Phase 3
38 Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases Completed NCT00540969 Phase 3
39 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes Completed NCT01106040 Phase 3
40 Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma Completed NCT00671918 Phase 3
41 PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma Recruiting NCT02288897 Phase 3
42 MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Recruiting NCT02385214 Phase 3
43 Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma Recruiting NCT02416232 Phase 3
44 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Recruiting NCT01729663 Phase 2, Phase 3
45 Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Recruiting NCT02339571 Phase 2, Phase 3
46 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting NCT02224781 Phase 3
47 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Recruiting NCT02506153 Phase 3
48 Melanoma Patients Immunized With Natural DenDritic Cells Recruiting NCT02993315 Phase 3
49 Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face Recruiting NCT01720407 Phase 3
50 Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna Recruiting NCT01088737 Phase 2, Phase 3

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Genetic tests related to Skin Melanoma:

id Genetic test Affiliating Genes
1 Cutaneous Melanoma 29

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

39
Skin, Testes, Lymph Node, Breast, T Cells, Endothelial, Colon

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 142)
id Title Authors Year
1
Seasonality of birth for skin melanoma deserves further investigation. ( 28338933 )
2017
2
Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. ( 28092675 )
2017
3
Health and Economic Burden of Skin Melanoma in Croatia - Cost-of-illness Study. ( 28511743 )
2017
4
Metallic copper nanoparticle induces apoptosis in human skin melanoma, A-375 cell line. ( 28067213 )
2017
5
Reply to: Seasonality of birth for skin melanoma deserves further investigation. ( 28338928 )
2017
6
Review and proposal of regional surgical management for melanoma: revisiting of integumentectomy and incontinuity dissection in treatment of skin melanoma. ( 28064397 )
2017
7
Prognostic significance of immunohistochemical epithelial-mesenchymal transition markers in skin melanoma patients. ( 27586584 )
2016
8
Expression of Molecular Markers of Angiogenesis, Lymphangiogenesis, and Proliferation Depending on the Stage of Skin Melanoma. ( 27590758 )
2016
9
A case report of gastroduodenal metastasis from skin melanoma. ( 27264432 )
2016
10
Anticancer properties of phospholipase A2 from Daboia siamensis venom on human skin melanoma cells. ( 26884744 )
2016
11
Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma. ( 27883322 )
2016
12
Fasting boosts sensitivity of human skin melanoma to cisplatin-induced cell death. ( 27693581 )
2016
13
ANTIPROLIFERATIVE EFFECT OF INOSITOL HEXAPHOSPHATE ON HUMAN SKIN MELANOMA CELLS IN VITRO. ( 26665395 )
2015
14
Demodex Mite, Rosacea and Skin Melanoma; Coincidence or Association? ( 25917583 )
2015
15
Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery. ( 26320440 )
2015
16
Negative HER2/neu amplification using immunohistochemistry and chromogenic in situ hybridization techniques in skin melanoma cases. ( 25684465 )
2015
17
Encapsulation of palladium porphyrin photosensitizer in layered metal oxide nanoparticles for photodynamic therapy against skin melanoma. ( 27877834 )
2015
18
Ginseng marc-derived low-molecular weight oligosaccharide inhibits the growth of skin melanoma cells via activation of RAW264.7 cells. ( 26548345 )
2015
19
Bringing Down Cancer Aircraft: Searching for Essential Hypomutated Proteins in Skin Melanoma. ( 26565620 )
2015
20
Calotropis procera extract induces apoptosis and cell cycle arrest at G2/M phase in human skin melanoma (SK-MEL-2) cells. ( 25623835 )
2015
21
Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. ( 26421821 )
2015
22
Evaluation of chemopreventive potentials of ethanolic extract of Ruta graveolens against A375 skin melanoma cells in vitro and induced skin cancer in mice in vivo. ( 25609370 )
2015
23
Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma. ( 24922189 )
2014
24
Cerium Oxide Nanoparticles Induce Oxidative Stress and Genotoxicity in Human Skin Melanoma Cells. ( 25395198 )
2014
25
Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. ( 24602025 )
2014
26
Oleanolic acid isolated from ethanolic extract of Phytolacca decandra induces apoptosis in A375 skin melanoma cells: drug-DNA interaction and signaling cascade. ( 24666676 )
2014
27
Analysis of the application of MMP-9 inhibitor in skin melanoma: experimental study. ( 23658876 )
2013
28
Ursolic acid differentially modulates apoptosis in skin melanoma and retinal pigment epithelial cells exposed to UV-VIS broadband radiation. ( 24375173 )
2013
29
Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. ( 23560814 )
2013
30
Homeopathic mother tincture of Phytolacca decandra induces apoptosis in skin melanoma cells by activating caspase-mediated signaling via reactive oxygen species elevation. ( 23506692 )
2013
31
Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. ( 23846221 )
2013
32
Ambient UVA-induced expression of p53 and apoptosis in human skin melanoma A375 cell line by quinine. ( 23336807 )
2013
33
Using SEER data to quantify effects of low income neighborhoods on cause specific survival of skin melanoma. ( 23803107 )
2013
34
Graveoline Isolated from Ethanolic Extract of Ruta graveolens Triggers Apoptosis and Autophagy in Skin Melanoma Cells: A Novel Apoptosis-Independent Autophagic Signaling Pathway. ( 24343999 )
2013
35
Chemoprevention of skin melanoma: facts and myths. ( 24077511 )
2013
36
Induction of oxidative stress, DNA damage, and apoptosis in a malignant human skin melanoma cell line after exposure to zinc oxide nanoparticles. ( 23493450 )
2013
37
Diagnostic value of intraoperative histopathological examination of the sentinel nodes in breast cancer and skin melanoma-Preliminary results of single centre retrospective study. ( 24416560 )
2013
38
Strategic formulation of apigenin-loaded PLGA nanoparticles for intracellular trafficking, DNA targeting and improved therapeutic effects in skin melanoma in vitro. ( 24070738 )
2013
39
HOX Gene Aberrant Expression in Skin Melanoma: A Review. ( 23091727 )
2012
40
Optimization of electron paramagnetic resonance imaging for visualization of human skin melanoma in various stages of invasion. ( 22509830 )
2012
41
Doppler ultrasound flowmetry predicts 15 year outcome in patients with skin melanoma. ( 23904713 )
2012
42
Skin melanoma sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin. ( 21923754 )
2012
43
Changes in the levels of N-cadherin and PCNA in skin melanoma cells are mediated through matrix metalloproteinase 9. ( 22866313 )
2012
44
The role of surgery in the treatment of colorectal metastases from primary skin melanoma. ( 22251405 )
2012
45
Design and simulation of a neutron source based on an electron linear accelerator for BNCT of skin melanoma. ( 21334211 )
2011
46
A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. ( 21334717 )
2011
47
Towards noncontact skin melanoma selection by multispectral imaging analysis. ( 21721796 )
2011
48
Sentinel lymph node biopsy in cases of skin melanoma: initial experiences at a center in northeastern Brazil. ( 21603830 )
2011
49
Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas. ( 21300445 )
2011
50
Morphological changes in human skin melanoma treated by high-energy pulsed neodymium laser radiation. ( 21766508 )
2011

Variations for Skin Melanoma

ClinVar genetic disease variations for Skin Melanoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CDKN2A NM_000077.4(CDKN2A): c.301G> T (p.Gly101Trp) single nucleotide variant Pathogenic,risk factor rs104894094 GRCh37 Chromosome 9, 21971057: 21971057

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 1862)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5611082 TRRAP skin,trunk,malignant melanoma,NS c.100C>T p.P34S 12
2 COSM1176879 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 12
3 COSM10726 TP53 skin,trunk,malignant melanoma,NS c.856G>A p.E286K 12
4 COSM328254 TNC skin,trunk,malignant melanoma,NS c.1342C>G p.R448G 12
5 COSM5610746 TBX22 skin,trunk,malignant melanoma,NS c.1352G>T p.G451V 12
6 COSM5610663 SMG7 skin,trunk,malignant melanoma,NS c.2811C>T p.F937F 12
7 COSM5610425 PTPRK skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 12
8 COSM5610317 PTPRD skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 12
9 COSM5142 PTEN skin,trunk,malignant melanoma,NS c.112C>T p.P38S 12
10 COSM231641 PREX2 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 12
11 COSM580 NRAS skin,trunk,malignant melanoma,NS c.181C>A p.Q61K 12
12 COSM585 NRAS skin,trunk,malignant melanoma,NS c.183A>T p.Q61H 12
13 COSM5049808 NF1 skin,ear,malignant melanoma,NS c.3652C>T p.Q1218* 12
14 COSM5609545 NF1 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 12
15 COSM5049807 NF1 skin,ear,malignant melanoma,NS c.3097C>T p.Q1033* 12
16 COSM5609467 MTOR skin,trunk,malignant melanoma,NS c.2638A>G p.T880A 12
17 COSM5609451 MSH6 skin,trunk,malignant melanoma,NS c.4004A>G p.E1335G 12
18 COSM232755 MAP2K1 skin,trunk,malignant melanoma,NS c.607G>A p.E203K 12
19 COSM5609259 KRAS skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12
20 COSM5609255 KIT skin,trunk,malignant melanoma,NS c.575G>A p.G192D 12
21 COSM5609145 IL36A skin,trunk,malignant melanoma,NS c.359C>T p.S120F 12
22 COSM110485 GRIN2A skin,ear,malignant melanoma,NS c.3217G>A p.E1073K 12
23 COSM109660 GRIN2A skin,ear,malignant melanoma,NS c.4097C>T p.P1366L 12
24 COSM5609011 GRIN2A skin,trunk,malignant melanoma,NS c.2252G>A p.G751E 12
25 COSM5608954 GNAQ skin,trunk,malignant melanoma,NS c.264G>T p.Q88H 12
26 COSM1205523 EPHB4 skin,trunk,malignant melanoma,NS c.2177C>T p.S726L 12
27 COSM5608400 EPHA3 skin,trunk,malignant melanoma,NS c.2525G>A p.R842Q 12
28 COSM141892 CNR1 skin,ear,malignant melanoma,NS c.145C>T p.P49S 12
29 COSM141856 CHRM3 skin,ear,malignant melanoma,NS c.1741T>A p.F581I 12
30 COSM13830 CDKN2A skin,trunk,malignant melanoma,NS c.341C>A p.P114H 12
31 COSM12503 CDKN2A skin,trunk,malignant melanoma,NS c.334C>G p.R112G 12
32 COSM13281 CDKN2A skin,trunk,malignant melanoma,NS c.205G>T p.E69* 12
33 COSM476 BRAF skin,trunk,malignant melanoma,NS c.1799T>A p.V600E 12
34 COSM1125 BRAF skin,ear,malignant melanoma,NS c.1790T>A p.L597Q 12
35 COSM27639 BRAF skin,ear,malignant melanoma,NS c.1780G>A p.D594N 12
36 COSM478 BRAF skin,ear,malignant melanoma,NS c.1801A>G p.K601E 12
37 COSM5610662 skin,trunk,malignant melanoma,NS c.2823C>T p.F941F 12
38 COSM1176880 skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 12
39 COSM5609544 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 12
40 COSM5610316 skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 12
41 COSM5611083 skin,trunk,malignant melanoma,NS c.100C>T p.P34S 12
42 COSM5609258 skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12
43 COSM235619 skin,trunk,malignant melanoma,NS c.461C>T p.S154F 12
44 COSM5610424 skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 12
45 COSM231642 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 12
46 COSM5609546 skin,trunk,malignant melanoma,NS c.568+1G>A p.? 12
47 COSM5610426 skin,trunk,malignant melanoma,NS c.2773G>A p.A925T 12
48 COSM5608955 skin,trunk,malignant melanoma,NS c.177G>T p.Q59H 12
49 COSM5611215 ZNF451 skin,neck,malignant melanoma,NS c.2114T>G p.I705S 11
50 COSM5611210 YAP1 skin,neck,malignant melanoma,NS c.1129C>T p.Q377* 11

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
2
Show member pathways
13.72 BRAF CDKN1A CDKN2A CDKN2B ERBB2 FGF2
3
Show member pathways
13.33 BRAF CASP3 CDKN1A ERBB2 FGF2 MMP2
4
Show member pathways
12.92 BRAF CDKN1A CDKN2A CDKN2B ERBB2 FGF2
5
Show member pathways
12.84 CASP3 CDKN1A CDKN2A NRAS TP53
6
Show member pathways
12.82 BRAF CASP3 ERBB2 NRAS PTGS2 TP53
7
Show member pathways
12.75 CDKN1A ERBB2 FGF2 NRAS TP53
8 12.72 BRAF CASP3 FGF2 NRAS TP53
9
Show member pathways
12.61 CDKN1A ERBB2 FGF2 MMP2 NRAS TP53
10
Show member pathways
12.54 BRAF CASP3 ERBB2 MMP2 MMP9 NRAS
11 12.48 CASP3 CDKN1A CDKN2A ERBB2 MMP9 NRAS
12
Show member pathways
12.46 CASP3 ERBB2 NRAS TP53
13 12.44 CDKN1A CDKN2A CDKN2B NRAS TP53
14
Show member pathways
12.39 CASP3 CDKN1A CDKN2A TP53
15 12.38 CDKN1A CDKN2A CDKN2B TP53
16
Show member pathways
12.37 MITF NRAS TP53 TYR
17
Show member pathways
12.37 CDKN1A CDKN2A CDKN2B TP53
18
Show member pathways
12.35 BRAF CASP3 CDKN1A ERBB2 MLH1 NRAS
19
Show member pathways
12.33 BRAF CDKN1A ERBB2 NRAS TP53
20 12.29 CASP3 CDKN1A CDKN2A CDKN2B NRAS TP53
21
Show member pathways
12.28 BRAF CASP3 MITF NRAS TP53
22
Show member pathways
12.2 BRAF CASP3 CDKN1A ERBB2 TP53
23
Show member pathways
12.16 BRAF CASP3 NRAS TP53
24
Show member pathways
12.12 BRAF CDKN1A CDKN2B NRAS
25 12.12 BRAF CASP3 CDKN1A ERBB2 FGF2 MMP2
26 12.1 CDKN1A CDKN2A MLH1 TP53
27
Show member pathways
12.1 BRAF CDKN1A CDKN2A ERBB2 NRAS TP53
28 12.09 CDKN1A MLH1 MMP2 TP53
29 12.08 BRAF CDKN1A NRAS TP53
30 12.08 BRAF CASP3 CDKN1A MLH1 MMP2 MMP9
31 12.06 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
32 12.04 CASP3 MMP9 PTGS2 TP53
33 12.01 CDKN1A CDKN2A ERBB2 NRAS TP53
34 12 BRAF CASP3 NRAS PTGS2
35 11.98 BRAF CDKN1A CDKN2A NRAS TP53
36 11.97 CDKN1A FGF2 MMP2 MMP9 PTGS2 TP53
37 11.96 BRAF CDKN1A CDKN2A TP53
38 11.86 FGF2 MMP2 MMP9 PTGS2
39 11.83 CDKN2B PTGS2 TP53
40
Show member pathways
11.82 BRAF CASP3 NRAS
41 11.81 MMP9 NME1 TP53
42 11.8 MITF MMP2 MMP9
43 11.79 CDKN1A NRAS PTGS2
44 11.75 CDKN1A CDKN2B ERBB2
45 11.72 CDKN1A CDKN2A MMP2 TP53
46 11.71 CASP3 CDKN1A CDKN2A ERBB2 MLH1 TP53
47 11.7 CASP3 MMP2 MMP9
48 11.69 ERBB2 NRAS TP53
49 11.69 CASP3 MMP2 MMP9
50 11.69 MITF NRAS TP53

GO Terms for Skin Melanoma

Cellular components related to Skin Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.5 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.98 BRAF CASP3 CDKN1A MMP9 TP53
2 angiogenesis GO:0001525 9.88 FGF2 MCAM MMP2 PTGS2
3 positive regulation of apoptotic process GO:0043065 9.83 CASP3 CDKN2A MMP9 PTGS2 TP53
4 response to glucocorticoid GO:0051384 9.74 CASP3 CDKN1A PTGS2
5 cellular response to drug GO:0035690 9.73 BRAF NME1 TP53
6 negative regulation of cell proliferation GO:0008285 9.73 CDKN1A CDKN2A CDKN2B NME1 PTGS2 TP53
7 cell cycle arrest GO:0007050 9.71 CDKN1A CDKN2A CDKN2B TP53
8 response to cAMP GO:0051591 9.7 BRAF NME1 TYR
9 response to UV GO:0009411 9.65 CASP3 CDKN1A TYR
10 embryo implantation GO:0007566 9.63 MMP2 MMP9 PTGS2
11 melanin biosynthetic process GO:0042438 9.59 PMEL TYR
12 negative regulation of fibroblast migration GO:0010764 9.55 BRAF FGF2
13 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.54 CASP3 CDKN1A CDKN2A
14 negative regulation of immature T cell proliferation in thymus GO:0033088 9.51 CDKN2A ERBB2
15 response to X-ray GO:0010165 9.5 CASP3 CDKN1A TP53
16 signal transduction by p53 class mediator GO:0072331 9.49 CDKN1A TP53
17 negative regulation of phosphorylation GO:0042326 9.33 CDKN1A CDKN2A CDKN2B
18 replicative senescence GO:0090399 9.13 CDKN1A CDKN2A TP53
19 Ras protein signal transduction GO:0007265 9.02 CDKN1A CDKN2A FGF2 NRAS TP53
20 phosphorylation GO:0016310 10.01 BRAF CDKN1A CDKN2A CDKN2B ERBB2 NME1

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 CDKN1A CDKN2A CDKN2B NME1 TP53
2 kinase activity GO:0016301 9.43 BRAF CDKN1A CDKN2A CDKN2B ERBB2 NME1
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CASP3 CDKN1A CDKN2A CDKN2B

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....